[go: up one dir, main page]

ATE241354T1 - Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis - Google Patents

Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis

Info

Publication number
ATE241354T1
ATE241354T1 AT95937658T AT95937658T ATE241354T1 AT E241354 T1 ATE241354 T1 AT E241354T1 AT 95937658 T AT95937658 T AT 95937658T AT 95937658 T AT95937658 T AT 95937658T AT E241354 T1 ATE241354 T1 AT E241354T1
Authority
AT
Austria
Prior art keywords
tetradecyloxy
disease
alzheimer
furane
psychosis
Prior art date
Application number
AT95937658T
Other languages
English (en)
Inventor
Eitan Friedman
M Katharine Holloway
Gideon A Rodan
Azriel Schmidt
Robert L Vogel
Original Assignee
Merck & Co Inc
Pennsylvania Med College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Pennsylvania Med College filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE241354T1 publication Critical patent/ATE241354T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
AT95937658T 1994-10-27 1995-10-24 Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis ATE241354T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/330,518 US5607967A (en) 1994-10-27 1994-10-27 Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
PCT/US1995/013931 WO1996013257A1 (en) 1994-10-27 1995-10-24 Use of receptor potentiators

Publications (1)

Publication Number Publication Date
ATE241354T1 true ATE241354T1 (de) 2003-06-15

Family

ID=23290124

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95937658T ATE241354T1 (de) 1994-10-27 1995-10-24 Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis

Country Status (9)

Country Link
US (1) US5607967A (de)
EP (1) EP0786995B1 (de)
JP (1) JP3881011B2 (de)
AT (1) ATE241354T1 (de)
AU (1) AU705987B2 (de)
CA (1) CA2200886A1 (de)
DE (1) DE69530933T2 (de)
ES (1) ES2198447T3 (de)
WO (1) WO1996013257A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726073A3 (de) * 1995-02-10 1998-07-08 Eduardo Samuel Bleiweiss Pharmazeutische Zusammensetzungen, welche mindestens eine von Haloperidol, Imipramine oder Trifluorperazine enthalten
WO1998039967A1 (en) * 1997-03-12 1998-09-17 The General Hospital Corporation A method for treating or preventing alzheimer's disease
EP1043980A2 (de) * 1997-10-28 2000-10-18 Schering Corporation Methode zur reduktion von suchterscheinungen bei säugern
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6890716B1 (en) * 1998-05-07 2005-05-10 Howard Hughes Medical Institute Recombinant cell line and screening method for identifying agents which regulate apoptosis and tumor suppression
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US20030086923A1 (en) * 1999-12-13 2003-05-08 Sparrow Carl P. Method for the prevention and/or treatment of atherosclerosis
US20020006959A1 (en) 2000-05-01 2002-01-17 Henderson Samuel T. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
GB0017951D0 (en) * 2000-07-22 2000-09-13 Univ Manchester Treatment of movement disorders
EP1377678A2 (de) * 2000-08-24 2004-01-07 EVOTEC Neurosciences GmbH DIAGNOSTISCHE UND THERAPEUTISCHE VERWENDUNG EINES CAVEOLAE-ASSOZIIERTEN INTERAlEN MEMBRANPROTEINS FÜR DIE ALZHEIMER ERKRANKUNG SOWIE VERWANDTE NEURODEGENERATIVE ERKRANKUNGEN
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) * 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US20030185884A1 (en) * 2002-04-01 2003-10-02 Singh Nikhilesh Nihala Therapeutic agent delivery compositions for buccal cavity absorption of pilocarpine
ES2361924T3 (es) * 2002-12-20 2011-06-24 X-Ceptor Therapeutics, Inc. Derivados de isoquinolinona y su uso como agentes terapéuticos.
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2005101007A1 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with liver x receptor beta (lxrb)
PT2001293T (pt) 2006-04-03 2018-11-28 Accera Inc Utilização de compostos cetogénicos para tratamento de comprometimento da memória associado à idade
JP2010527360A (ja) * 2007-05-14 2010-08-12 ニューエラ・ファーマシューティカルズ・インコーポレーテッド 神経細胞の代謝低下の処置のためのアセチル−ｃｏａカルボキシラーゼの阻害剤
WO2009018478A2 (en) 2007-07-31 2009-02-05 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
BRPI0912679A2 (pt) * 2008-05-16 2016-01-26 Axis Inc composição farmacêutica para o tratamento de fibromialgia
US9125881B2 (en) * 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
DK2872145T3 (da) * 2012-07-12 2022-06-13 Emalex Biosciences Inc Kondenserede benzazepiner til behandling af tourettes syndrom
CN110833621A (zh) * 2019-12-06 2020-02-25 中国医科大学 多巴胺受体1拮抗剂在制备治疗对氯胺酮致小鼠类精神分裂症药物上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601247A1 (fr) * 1986-07-09 1988-01-15 Merk Sharp Dohme Chibret Labor Combinaison d'agents beta-bloquants et de pilocarpine.
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5153205A (en) * 1990-10-01 1992-10-06 Merck & Co., Inc. Method to reduce introacular pressure without causing miosis
ATE225167T1 (de) * 1992-07-24 2002-10-15 Univ Johns Hopkins Verwendung von inhibitoren der synthese von fettsäuren zur behandlung von krebs

Also Published As

Publication number Publication date
EP0786995B1 (de) 2003-05-28
ES2198447T3 (es) 2004-02-01
EP0786995A1 (de) 1997-08-06
DE69530933D1 (de) 2003-07-03
JPH10509139A (ja) 1998-09-08
JP3881011B2 (ja) 2007-02-14
CA2200886A1 (en) 1996-05-09
WO1996013257A1 (en) 1996-05-09
EP0786995A4 (de) 1997-08-20
DE69530933T2 (de) 2004-02-12
AU3970095A (en) 1996-05-23
AU705987B2 (en) 1999-06-03
US5607967A (en) 1997-03-04

Similar Documents

Publication Publication Date Title
ATE241354T1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE231724T1 (de) Kombinationstherapie für die behandlung von psychosen
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE68913667D1 (de) Imidazole für die Behandlung von Atherosclerose.
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
SE9502921D0 (sv) New compounds
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
IT8320435A0 (it) Composizione per il trattamento dell'acne.
DE69007486D1 (de) Verwendung von calciumantagonisten für die behandlung von narben.
DE69622889D1 (de) Substituierte 4-(1h-benzimidazol-2-yl)(1,4)diazepane für die behandlung von allergischen krankheiten
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE3856329D1 (de) Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
DE69013871D1 (de) 4-Benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
BR0012921A (pt) Compostos calcilìticos
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
ATE330604T1 (de) Behandlung von manischen erkrankungen
SE9504618D0 (sv) New Compounds
DE69917445D1 (de) Reinigung von carboxaldehyd

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties